[ad_1]
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-524975736-a2f20e95c6cc4097a8f5843c05e4ef8f.jpg)
Pfizer Inc.: An Overview
Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company headquartered in New York. It researches, develops, and manufactures biopharmaceutical products for use in the treatment of cancer, cardiovascular disease, inflammatory diseases, immunology, and rare diseases. It also develops and manufactures vaccines.
Pfizer collaborated with German biotech company BioNTech SE (BNTX) to develop one of the world’s most widely used mRNA-based vaccines against COVID-19. The vaccine was approved by the U.S. Food and Drug Administration (FDA) in August 2021, becoming the first COVID-19 vaccine to gain full approval for use in the U.S.
More recently, it received FDA approval in February 2025 for a new treatment for an aggressive form of lymphoma. It won FDA approval for a new treatment for hemophilia in October 2024.
The top insider shareholders of Pfizer are Albert Bourla, chairman and CEO; Mikael Dolsten, retiring chief scientific officer, and Douglas Lankler, executive vice president, according to the company’s proxy statement for 2024.
The top institutional shareholders of Pfizer as of the end of 2024 are Vanguard Group, Blackrock Inc., and State Street Corp.
Pfizer’s net income for the 12 months ended April 20, 2025, was $8.02 billion, while revenue for the same period was $63.63 billion. The company’s market capitalization was $125.56 billion as of the same date.
Key Takeaways
- Pfizer is a pharmaceutical and biotechnology company that developed a COVID-19 vaccine that was approved by the FDA in August 2021.
- The three top individual/insider shareholders in Pfizer are Albert Bourla, Mikael Dolstenand, and Douglas Lanker
- The three top institutional shareholders are Vanguard Group, BlackRock, and State Street.
Top 3 Individual/Insider Shareholders
About 0.06% of Pfizer’s shares are held by insiders, who are executives or board members of the company.
The shares noted below are held directly by individual shareholders. The totals do not include shares held indirectly (through other individuals or entities) nor shares accessible through stock options.
Albert Bourla
Dr. Albert Bourla holds 316,799 shares of Pfizer as of the company’s 2024 proxy statement.
Bourla has been chairman and chief executive officer (CEO) of Pfizer since 2019. He has been with the company for more than 30 years.
Under his leadership, Pfizer delivered the first FDA-authorized oral antiviral treatment for COVID-19. Based on this success, he’s taken the same urgent-need approach to therapeutic projects aimed at cancer, cardiovascular disease, inflammatory conditions, and more.
Mikael Dolsten
Mikael Dolsten, retired Chief Scientific Officer and head of Pfizer’s Research & Development division, owns 174,395 shares as of the company’s 2024 proxy statement.
His successor, former Chief Oncology Officer Chris Boshoff, took over the position at the beginning of 2025.
Dolsten was at Pfizer for 15 years. His focus was on developing scientific breakthroughs in small-molecule medicines, biotherapeutics, gene therapies, and vaccines.
Douglas Lanker
Douglas Lanker owns 136,997 shares of Pfizer as of the company’s 2024 proxy statement.
Lanker is Pfizer’s chief legal officer and an executive vice president. He is a former Assistant U.S. Attorney for the Southern District of New York and has been on Pfizer’s management team since 2009.
Important
The term insider refers to people in senior management positions and members of the board of directors, as well as people or entities that own more than 10% of the company’s stock.
Top 3 Institutional Shareholders
Institutional investors hold 67.74% of Pfizer’s total shares outstanding.
Vanguard Group
Vanguard Group held more than 518 million shares of Pfizer as of Dec. 31, 2024.
Vanguard is primarily a mutual fund and exchange-traded fund (ETF) management company with about $9.3 trillion in global assets under management (AUM).
The Vanguard S&P 500 ETF (VOO) is one of the company’s largest ETFs with more than $570 billion in AUM. Pfizer comprises 0.3% of VOO’s holdings.
BlackRock
BlackRock owned 432.5 million Pfizer shares as of the end of 2024.
BlackRock is primarily a mutual fund and ETF management company. It has about $10 trillion in AUM.
The iShares Core S&P 500 ETF (IVV) is one of BlackRock’s largest ETFs with approximately $450.03 billion in AUM. Pfizer comprises 0.28% of IVV’s holdings.
State Street
State Street held more than 290 million shares of Pfizer as of the end of 2024.
It owns Pfizer shares via its investment management arm, State Street Global Advisors. State Street is primarily a manager of mutual funds, ETFs, and other assets with about $4.13 trillion in AUM.
The SPDR S&P 500 ETF Trust (SPY) is one of State Street’s largest ETFs with about $546 billion in AUM. Pfizer comprises about 0.28% of SPY’s holdings.
What Is Pfizer’s Business Focus?
Pfizer is a pharmaceutical and biotechnology company focused on driving medical innovations and delivering medicines throughout the world, especially to communities without the level of access to healthcare that others enjoy.
What Vaccines Has Pfizer Created?
Pfizer developed a COVID-19 vaccine in eight months. This vaccine has been delivered to millions across the world.
In August 2023, the FDA approved the company’s maternal vaccine to prevent and protect infants from the respiratory syncytial virus from birth to six months of age. In October 2024, Pfizer received FDA approval for the first RSV vaccine for adults younger than age 50.
Does Pfizer Pay Dividends to Shareholders?
Yes. Pfizer has paid dividends to its shareholders for 345 consecutive quarters as of the first quarter of 2025. Most recently, it paid a dividend of 0.43 cents per share for the first quarter of 2025.
The Bottom Line
Pfizer is a global pharmaceutical and biotechnology company with headquarters in New York. It developed a successful vaccine against COVID-19. The top three institutional investors in Pfizer are Vanguard, BlackRock, and State Street. Most of their investments in Pfizer are held in S&P 500 Index funds.
[ad_2]
Source link
